Dernières nouvelles pour Molina Healthcare (NYSE:MOH) Stock

Molina Healthcare

Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.

Molina Healthcare Inc

MOTOR OIL HELLAS CORINTH by Motor Oil (Hellas) Corinth Refineries S.A.

Motor Oil (Hellas) Corinth Refineries SA

MOTOR OIL HELLAS UNSP/ADR by Motor Oil (Hellas) Corinth Refineries S.A.

ECMOHO Ltd

Collaborative Investment Series Trust Mohr Growth ETF

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 10 years by 10.92% on an annualized basis producing an average annual return of 22.8%. Currently, Molina Healthcare has a market capitalization of $19.04 billion. 
Buying $100 In MOH: If an investor had bought $100 of MOH stock 10 years ago, it would be worth $778.30 today based on a price of $324.93 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728500417_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$100 Invested In Molina Healthcare 10 Years Ago Would Be Worth This Much Today

UnitedHealth Group Incorporated (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/unh#NYSE">UNH</a>) is set to report third-quarter 2024 results on Oct. 15, 2024, before the opening bell. The Zacks Consensus Estimate for the to-be-reported quarter&#39;s earnings is currently pegged at $7.02 per share on revenues of $99.6 billion.&nbsp;Growing premiums, commercial memberships and Optum business are expected to have supported its performance, partially affected by elevated expenses and lower Medicaid memberships.
The third-quarter earnings estimate has witnessed downward revisions over the past 60 days. However, the bottom-line projection indicates a year-over-year increase of 7%. The Zacks Consensus Estimate for quarterly revenues suggests year-over-year growth of 7.8%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/ea/80943.jpg?v=1460002441" style="border-style:solid; border-width:1px; height:310px; width:600px" />
Image Source: Zacks Investment Research
UnitedHealth has a robust history of surpassing earnings estimates, beating the consensus estimate in each of the last four quarters, with the average surprise being 3.3%.
<div class="chart_embed">
<h2>UnitedHealth Group Incorporated Price and EPS Surprise</h2>
<img alt="UnitedHealth Group Incorporated Price and EPS Surprise" src="https://staticx-tuner.zacks.com/images/charts/4b/1728478380.png" style="border-style:solid; border-width:1px; height:310px; width:600px" title="" />
UnitedHealth Group Incorporated price-eps-surprise | UnitedHealth Group Incorporated Quote
</div>
<h2>Q3 Earnings Whispers for UNH</h2>
However, our proven model does not conclusively predict an earnings beat for the company this time around. The combination of a positive&nbsp;Earnings ESP&nbsp;and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. That&#39;s not the case here.
UNH has an Earnings ESP of 0.00% and a Zacks Rank #4 (Sell).
<h2>What&#39;s Shaping Q3 Results?</h2>
UnitedHealth&#39;s third-quarter earnings are expected to have benefited from higher premiums, driven by the expansion of its commercial membership base. The Zacks Consensus Estimate for premium revenues for the third quarter indicates 6.1% year-over-year growth, whereas our model estimate suggests a 5.3% increase. Increased contributions from both Optum Health and its health benefits divisions are expected to have supported premium growth.
UNH&#39;s third-quarter top-line performance is expected to have been enhanced by a rise in service revenues in Optum Health and OptumRX. The consensus estimate implies an almost 6% jump in service revenues. Similarly, we expect product revenues to have seen more than 18% year-over-year growth, while the Zacks Consensus Estimate indicates a&nbsp;nearly 18% increase.
A rise in the number of people being catered to in value-based care arrangements, enhanced technology-enabled offerings, and growth in its specialty and community-based pharmacy offerings are likely major tailwinds for the company&#39;s results. The Zacks Consensus Estimate for operating income from the Optum business segment suggests a 15.8% year-over-year increase. These are expected to have positioned the company for year-over-year growth in the third quarter.
However, Optum survived a blow from a cyber-attack on its Change Healthcare business in the first quarter. The company expects to incur direct response costs in the range of $1.30-$1.35 per share for 2024, along with a business disruption impact of 60-70 cents. These factors are expected to have partially affected its profit growth levels in the third quarter.
Now let&#39;s focus on memberships in selected programs. The Zacks Consensus Estimate for UnitedHealthcare&#39;s total domestic commercial customers suggests 7.7% year-over-year growth. The consensus mark for Medicare Advantage members indicates a 3.2% year-over-year rise, whereas our estimate implies a 4.5% gain.
However, the consensus estimate for Medicaid memberships implies a 7.1% decline from the year-ago level, while our model estimate suggests a 7.6% slip. Also, the consensus mark for international memberships indicates a nearly 73% year-over-year plunge. This is likely to have pulled total memberships down from the year-ago period. Both the consensus estimate and our model estimate imply a 4.8% fall year over year.
Rising medical costs, as seniors continued resuming elective proceduresare expected to have elevated UnitedHealth&#39;s overall expenses in the quarter. The expected growth in healthcare utilization, especially in the Medicare Advantage space, might have affected margins. We expect higher costs of products sold to have further reduced its margins. Our model estimate for total operating costs indicates an 8% increase from the prior-year period.
The Zacks Consensus Estimate for UNH&#39;s medical care ratio is pegged at 84.31%, up from 82.30% in the year-ago quarter. Our estimates for medical costs and costs of products soldindicate 7.9% and 20.8% year-over-year increases, respectively. The Zacks Consensus Estimate for operating income from UnitedHealthcare indicates a&nbsp;nearly 5% year-over-year decline, making an earnings beat uncertain this time around.
<h2>Price Performance &amp; Valuation</h2>
UnitedHealth&#39;s stock has gained 10.5% year to date, outperforming the industry&#39;s growth of 5.2%. Some of its peers like Humana Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hum#NYSE">HUM</a>) and Molina Healthcare, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/moh#NYSE">MOH</a>) have plunged 46.9% and 10.1%, respectively, during this time. All these stocks have lagged the S&amp;P 500 significantly, which has rallied 19.5% during the same period.
<h2>YTD Price Performance</h2>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/6f/80945.jpg?v=1300761784" style="border-style:solid; border-width:1px; height:310px; width:600px" />
Image Source: Zacks Investment Research
Now, let&#39;s look at the value UnitedHealth offers investors at current levels.
The company&#39;s valuation looks somewhat stretched compared with the industry average. Currently, UNH is trading at 19.13X forward 12 months earnings, above its five-year median of 19.08X and the industry&#39;s average of 16.22X.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/16/80944.jpg?v=439523203" style="border-style:solid; border-width:1px; height:310px; width:600px" />
Image Source: Zacks Investment Research
<h2>Assessing UnitedHealth&#39;s Prospects</h2>
UnitedHealth&#39;s diversified portfolio and strategic growth initiatives in home healthcare, commercialbusiness and AI-driven analytics offer promising long-term growth prospects. Its estimated earnings growth rate of 13% for the next five years compares favorably with the industry average of 10.6%. The company continues to reward shareholders with substantial dividends and share repurchases, underpinned by strong cash flow and operational resilience.
However, challenges such as the impacts of the recent cyber-attack, regulatory investigations, margin pressures due to lower-than-expected Medicare rates and rising medical costs could limit short-term stock performance. Declining membership in the global business and higher medical care ratio can be causes of concern. Investors should closely monitor these factors.
<h2>Final Words</h2>
While UNH&#39;s long-term outlook remains promising, it might not be the right time to buy just yet. Investors should stay patient and wait for a better entry point, as rushing in now could limit potential gains. Current shareholders may want to consider locking in profits, given that the stock appears overvalued and has minimal room for further growth in the short term.
<a href="https://www.zacks.com/stock/news/2348376/unitedhealth-pre-q3-earnings-golden-opportunity-or-fool-s-gold?cid=CS-BENZ-FT-analyst_blog|most_popular_stocks-2348376">To read this article on Zacks.com click here.</a>

Earnings

Earnings Beats

Large Cap

Dividends

Health Care

Offerings

Markets

Analyst Ratings

General

UnitedHealth Pre-Q3 Earnings: Golden Opportunity or Fool's Gold?

Michael Burry, the investor renowned for his prescient bet against the housing market before the 2008 financial crisis, has seen his recent wager on <a href="https://www.benzinga.com/markets/asia/24/08/40386342/big-short-fame-michael-burry-bets-big-on-china-reveals-alibaba-as-top-holding-jd-com-and-baidu-also">Chinese stocks yield significant returns</a>. 
What Happened: Burry&#8217;s top three Chinese holdings have surged an average of 59.39% within two months, according to regulatory filings and market data.
Burry&#8217;s hedge fund, Scion Asset Management, made substantial changes to its portfolio in the second quarter of 2024. The fund&#8217;s latest 13F report, filed with the U.S. Securities and Exchange Commission on Aug. 14, revealed a notable shift toward Chinese tech giants.
Alibaba Group Holding Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>), Burry&#8217;s largest Chinese position with 155,000 shares, saw its stock price climb from $73.40 on the filing date to a peak of $117.52 on Monday — a 60.11% increase. The stock has since retreated to $91.94 amid a <a href="https://www.benzinga.com/markets/asia/24/10/41243227/chinese-stocks-plunge-as-hang-seng-drops-1-39-extending-volatile-streak-tech-giants-jd-com-alibaba-b">broader sell-off in Chinese equities</a>.
Baidu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>), in which Scion holds 75,000 shares, experienced a 36.29% surge from $83.99 to a Monday high of $114.47. It now trades at $106.01.
JD.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>), representing Burry&#8217;s third-largest Chinese bet with 250,000 shares, skyrocketed 81.78% from $25.90 to $47.08 before settling at $43.54.
The impressive gains in these Chinese stocks stand in stark contrast to the performance of Burry&#8217;s American holdings. Molina Healthcare Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has dropped 4.11% over the same period, while Shift4 Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) has risen a more modest 13.26%.
See Also: <a href="https://www.benzinga.com/markets/equities/24/10/41246126/ray-dalio-issues-stark-warning-as-investors-get-optimistic-about-china-again-theres-something-bi">Ray Dalio Issues Stark Warning As Investors Get Optimistic About China Again: &#8216;There&#8217;s Something Big Going On&#8230;&#8217;</a>
Why It Matters: Burry&#8217;s pivot to Chinese equities came just before a significant rally in the sector, fueled by expectations of government stimulus. However, the rally faltered on Monday when Beijing&#8217;s announced <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41227136/chinese-stocks-plunge-as-stimulus-hopes-fade-hong-kong-posts-worst-daily-decline-si">measures fell short of market expectations</a>.
The investor&#8217;s other notable holdings include The RealReal Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAL#NASDAQ">REAL</a>), Olaplex Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLPX#NASDAQ">OLPX</a>), and American Coastal Insurance Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>). BioAtla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>), a clinical-stage biopharmaceutical company, also represents a smaller position in the portfolio.
Earlier this year, Burry made headlines for substantial investments in gold and renewable energy while <a href="https://www.benzinga.com/markets/asia/24/05/38878116/big-short-investor-michael-burry-bets-heavy-on-gold-renewable-energy-stocks-exits-amazon-alphabet">exiting positions in major U.S. tech companies</a> like Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>).
Investors should note that 13F reports, typically filed 45 days after each quarter&#8217;s end, only disclose holdings in U.S. equity securities and do not provide information on the timing of purchases or sales, <a href="https://www.sec.gov/divisions/investment/13ffaq">according</a> to the SEC. While these reports offer valuable insights into market trends and institutional strategies, they represent a snapshot of holdings at a specific point in time.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41247174/us-stocks-set-to-open-marginally-lower-nvidia-gains-traders-eye-fed-minutes-strategist-predicts-man">US Stocks Set To Open Marginally Lower, Nvidia Gains, Traders Eye Fed Minutes: Strategist Predicts Many More Years Of Gains Ahead Of Bull Market&#8217;s 2nd Anniversary</a></li>
</ul>
Michael Burry&#8217;s illustration was created using artificial intelligence.
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Equities

ACIC

AMZN

BABA

BCAB

BIDU

FOUR

GOOG

GOOGL

OLPX

REAL

'Big Short' Investor Michael Burry's China Bet Pays Off As Top Picks Surge Nearly 60% In 2 Months

Shares of&nbsp;Humana Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hum#NYSE">HUM</a>) have dropped 30.2% over the past month to close at $240.03 on Friday. The steep declines last week have pushed the stock&#39;s price closer to the lower end of its 52-week range of $213.31-$530.54. Having underperformed its peers like&nbsp;Molina Healthcare, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/moh#NYSE">MOH</a>) and Centene Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cnc#NYSE">CNC</a>), the overall industry, and the S&amp;P 500, the company&#39;s current share price seems an excellent opportunity to build a position in a renowned HMO company. After all, you would much rather buy closer to the low than the high, right?&nbsp;
<h2>One-Month Price Performance</h2>
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/e4/80609.jpg?v=334232142" style="border-style:solid; border-width:1px; height:310px; width:600px" />
Image Source: Zacks Investment Research
HUM is trading below its 50 and 200-day moving averages, indicating a bearish outlook. Buying closer to the low can be attractive, but context matters - let&#39;s explore further.
<h2>HUM&#39;s Falling Stars</h2>
HUM experienced its worst share price fall since the financial crisis due to losing high-quality ratings on its major Medicare Advantage plans, which generate substantial revenue. The news slashed its star-rated membership from 94% to around 25%, triggering a selloff that wiped out a massive chunk of its market value.
This has not only affected Humana but also rippled through the broader health insurance sector. The health insurer, like many others, is already facing growing medical costs and tighter reimbursements from the government. This latest development is bound to affect its profit levels.
<h2>Analysts Downgrade HUM&#39;s Earnings Estimates</h2>
Reflecting the negative sentiment around Humana, the Zacks Consensus Estimate for earnings per share has seen downward revisions. The consensus estimate for 2024 adjusted earnings for HUM is currently pegged at $16.12 per share, indicating a 38.2% year-over-year decline. Over the past four quarters, its average earnings surprise is at negative 2.5%.
<img alt="Zacks Investment Research" src="https://staticx-tuner.zacks.com/images/articles/charts/9b/80608.jpg?v=386647277" style="border-style:solid; border-width:1px; height:310px; width:600px" />
Image Source: Zacks Investment Research
<h2>HUM&#39;s Headwinds</h2>
With a sharp decline expected in Humana&#39;s top-rated Medicare Advantage plan enrollments next year, its revenues are likely to take a hit. This drop is expected to ripple through its partner network, affecting them depending on payment structures. The company has already been dealing with an anticipated membership decline, and this new development further hinders its member growth strategies.
In addition, Humana has been grappling with rising operating expenses. Over the past few years, operating costs surged 10.7% in 2021, 11.5% in 2022, and 14.9% in 2023. The trend has continued, with a 12.8% increase in operating expenses reported in the first half of 2024. The rise is attributed to higher benefits and operating costs, which are likely to pressure profit margins moving forward. Moreover, as senior citizens continue to resume elective procedures post-pandemic, medical costs are set to escalate further, adding to the company&#39;s financial challenges.
Also, its rising debt level is a concern. Long-term debt amounted to $11.7 billion at second-quarter end, up 15% from the figure as of Dec. 31, 2023.&nbsp;Its long-term debt to capital of 41.25% is higher than the industry average of 38.26%.
<h2>Final Words: Steer Clear of HUM Stocks</h2>
Humana is facing significant challenges, including membership decline, rising costs and debt burden. The stock is trading below key moving averages, signaling a bearish trend. With analysts downgrading earnings estimates, investors should approach HUM stock with caution as it shows serious downside potential. It currently carries a Zacks Rank #4 (Sell).
<a href="https://www.zacks.com/stock/news/2347052/humana-stock-getting-closer-to-52-week-lows-a-buying-opportunity?cid=CS-BENZ-FT-analyst_blog|52week_high/low-2347052">To read this article on Zacks.com click here.</a>

Humana Stock Getting Closer to 52-Week Lows: A Buying Opportunity?

In the preceding three months, 14 analysts have released ratings for Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), presenting a wide array of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $371.36, a high estimate of $406.00, and a low estimate of $297.00. This current average represents a 3.2% decrease from the previous average price target of $383.64. 
<img src="https://www.benzinga.com/files/images/story/2024/1727802103_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of Molina Healthcare's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$406.00</td>
<td>$406.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$406.00</td>
<td>$406.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$406.00</td>
<td>$406.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$360.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$353.00</td>
<td>$354.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$378.00</td>
<td>$351.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$406.00</td>
<td>$406.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$351.00</td>
<td>$412.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$297.00</td>
<td>$354.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$406.00</td>
<td>$406.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$315.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$400.00</td>
<td>$440.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$395.00</td>
<td>$420.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Molina Healthcare. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Molina Healthcare compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Molina Healthcare's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Molina Healthcare's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MOH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Molina Healthcare analyst ratings.</a>
<h2>Unveiling the Story Behind Molina Healthcare</h2>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Molina Healthcare's Financial Performance</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Positive Revenue Trend: Examining Molina Healthcare's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 18.65% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Molina Healthcare's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 3.05%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Molina Healthcare's ROE stands out, surpassing industry averages. With an impressive ROE of 6.45%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Molina Healthcare's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.96% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.49, Molina Healthcare adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For Molina Healthcare

Cantor Fitzgerald analyst Sarah James reiterates Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Overweight and maintains $406 price target.

Price Target

Reiteration

Cantor Fitzgerald Reiterates Overweight on Molina Healthcare, Maintains $406 Price Target

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 10 years by 12.09% on an annualized basis producing an average annual return of 23.31%. Currently, Molina Healthcare has a market capitalization of $20.58 billion. 
Buying $100 In MOH: If an investor had bought $100 of MOH stock 10 years ago, it would be worth $791.70 today based on a price of $351.12 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726862566_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Molina Healthcare Stock In The Last 10 Years

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has been analyzed by 13 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $368.69, a high estimate of $406.00, and a low estimate of $297.00. Observing a downward trend, the current average is 3.46% lower than the prior average price target of $381.92. 
<img src="https://www.benzinga.com/files/images/story/2024/1725998420_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of Molina Healthcare by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$406.00</td>
<td>$406.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$406.00</td>
<td>$406.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$360.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$353.00</td>
<td>$354.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$378.00</td>
<td>$351.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$406.00</td>
<td>$406.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$351.00</td>
<td>$412.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$297.00</td>
<td>$354.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$406.00</td>
<td>$406.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$315.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$400.00</td>
<td>$440.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$395.00</td>
<td>$420.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Molina Healthcare. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Molina Healthcare compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Molina Healthcare's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Molina Healthcare's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MOH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Molina Healthcare analyst ratings.</a>
<h2>Get to Know Molina Healthcare Better</h2>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Financial Insights: Molina Healthcare</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Molina Healthcare's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 18.65% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Molina Healthcare's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 3.05%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Molina Healthcare's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 6.45%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Molina Healthcare's ROA stands out, surpassing industry averages. With an impressive ROA of 1.96%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Molina Healthcare's debt-to-equity ratio is below the industry average at 0.49, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Molina Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) short percent of float has fallen 16.12% since its last report. The company recently reported that it has 1.58 million shares sold short, which is 3.07% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.42 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Molina Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725976812_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Molina Healthcare has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Molina Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Molina Healthcare's peer group average for short interest as a percentage of float is 3.65%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Molina Healthcare's Recent Short Interest

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 15 years by 11.8% on an annualized basis producing an average annual return of 23.48%. Currently, Molina Healthcare has a market capitalization of $20.70 billion. 
Buying $1000 In MOH: If an investor had bought $1000 of MOH stock 15 years ago, it would be worth $24,065.93 today based on a price of $353.21 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725478210_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Molina Healthcare Stock In The Last 15 Years

Investors in Molina Healthcare, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/moh#NYSE">MOH</a>) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 20, 2024 $270.00 Call had some of the highest implied volatility of all equity options today.
<h2>What is Implied Volatility?</h2>
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
<h2>What do the Analysts Think?</h2>
Clearly, options traders are pricing in a big move for Molina Healthcare shares, but what is the fundamental picture for the company? Currently, Molina Healthcare is a Zacks Rank #3 (Hold) in the Medical - HMOs industry that ranks in the Bottom 10% of our Zacks Industry Rank. Over the last 30 days, one analyst has increased the earnings estimates for the current quarter, while four have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from earnings of $5.95 per share to $6.02 in that period.
Given the way analysts feel about Molina Healthcare right now, this huge implied volatility could mean there&#39;s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
<a href="https://www.zacks.com/stock/news/2327124/do-options-traders-know-something-about-molina-healthcare-moh-stock-we-don-t?cid=CS-BENZ-FT-tale_of_the_tape|options-2327124">To read this article on Zacks.com click here.</a>

Options

Do Options Traders Know Something About Molina Healthcare Stock We Don't?

Molina Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) short percent of float has fallen 16.12% since its last report. The company recently reported that it has 1.58 million shares sold short, which is 3.07% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.42 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Molina Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724253315_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Molina Healthcare has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Molina Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Molina Healthcare's peer group average for short interest as a percentage of float is 4.21%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Molina Healthcare's Recent Short Interest

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 20 years by 6.84% on an annualized basis producing an average annual return of 15.24%. Currently, Molina Healthcare has a market capitalization of $20.51 billion. 
Buying $1000 In MOH: If an investor had bought $1000 of MOH stock 20 years ago, it would be worth $16,747.68 today based on a price of $349.97 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724090416_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $17,000 Today

Famed investor Michael Burry, known for his prescient bet against the housing market before the 2008 financial crisis, has made significant changes to his hedge fund&#8217;s portfolio in the second quarter of 2024. 
What Happened: Scion Asset Management, based in Saratoga and run by Burry, filed its latest 13F report with the U.S. Securities and Exchange Commission on Wednesday, revealing a notable shift in investment strategy.
Key Highlights:
<ol>
<li>Alibaba Group Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) Takes Top Spot: Chinese e-commerce giant Alibaba has become Scion&#8217;s largest holding, with a position valued at approximately $11.16 million, consisting of 155,000 shares.</li>
<li>Tech Focus: The portfolio shows a continued interest in Chinese tech companies, with significant positions in Baidu Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) with 75,000 shares valued at $6.49 million, and JD.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) with 250,000 shares valued at $6.46 million.</li>
<li>Healthcare and Fintech: Molina Healthcare Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) and Shift4 Payments Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) represent substantial investments, valued at $7.29 million and $7.34 million respectively.</li>
<li>Real Estate Exposure: Hudson Pacific Properties Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPP#NYSE">HPP</a>) stands out as a significant real estate play, with over 1.1 million shares valued at $5.50 million.</li>
<li>Emerging Biotech: BioAtla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>), a clinical-stage biopharmaceutical company, represents a smaller but noteworthy position in the portfolio.</li>
</ol>
Other notable holdings include The RealReal Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAL#NASDAQ">REAL</a>), Olaplex Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLPX#NASDAQ">OLPX</a>), and American Coastal Insurance Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>).
See Also: <a href="https://www.benzinga.com/markets/equities/24/08/40329069/cathie-wood-seizing-low-valuation-opportunity-among-magnificent-7-ark-invest-snaps-up-2-4m-in-al?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Cathie Wood Seizing Low-Valuation Opportunity Among Magnificent 7? Ark Invest Snaps Up $2.4M In Alphabet Shares</a>
Why It Matters: This latest filing offers insight into Burry&#8217;s current market outlook, suggesting a diverse approach with significant bets on Chinese technology firms, U.S. healthcare, fintech, and select real estate opportunities. 
In May, Burry made headlines for his substantial investments in <a href="https://www.benzinga.com/markets/asia/24/05/38878116/big-short-investor-michael-burry-bets-heavy-on-gold-renewable-energy-stocks-exits-amazon-alphabet">gold and renewable energy</a>, while exiting positions in major tech companies like Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>). This pivot indicated a focus on physical commodities and sustainable energy sources.
In a related development, a <a href="https://www.benzinga.com/general/entertainment/24/07/39695004/elon-musk-warren-buffett-nancy-pelosi-jensen-huang-michael-saylor-who-you-sitting-by-on-a-p">recent poll highlighted </a>how investors seek advice from top figures like Elon Musk, Warren Buffett, and Burry himself, underscoring his influence in the investment community.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/08/40303410/warren-buffett-declares-shift-selling-apple-stock-to-invest-in-this-magnificent-megacap-heres-why?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Warren Buffett Declares Shift: Selling Apple Stock To Invest In This &#8216;Magnificent&#8217; Megacap – Here&#8217;s Why</a></li>
</ul>
Michael Burry illustration by Gonzalo Lanzilotta for
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Asia

Global

'Big Short' Fame Michael Burry Bets Big On China, Reveals Alibaba As Top Holding — JD.com And Baidu Also Feature On Scion's Portfolio

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 10 years by 12.81% on an annualized basis producing an average annual return of 23.34%. Currently, Molina Healthcare has a market capitalization of $19.74 billion. 
Buying $100 In MOH: If an investor had bought $100 of MOH stock 10 years ago, it would be worth $830.16 today based on a price of $336.88 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1723150830_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Wells Fargo analyst Stephen Baxter maintains Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Equal-Weight and raises the price target from $315 to $360.

Wells Fargo Maintains Equal-Weight on Molina Healthcare, Raises Price Target to $360

Revealing a significant insider sell on July 30, Jeff D Barlow, Chief Legal Officer at Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), as per the latest SEC filing.
What Happened: Barlow's decision to sell 5,340 shares of Molina Healthcare was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001179929/000117992924000126//Archives/edgar/data/1179929/000117992924000126/0001179929-24-000126-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The total value of the sale is $1,788,900.
At Wednesday morning, Molina Healthcare shares are down by 1.13%, trading at $346.76.
<h3>Get to Know Molina Healthcare Better</h3>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Financial Milestones: Molina Healthcare's Journey</h3>
Revenue Growth: Over the 3 months period, Molina Healthcare showcased positive performance, achieving a revenue growth rate of 18.65% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 12.29%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Molina Healthcare's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 5.18.
</li>
</ul>
Debt Management: Molina Healthcare's debt-to-equity ratio surpasses industry norms, standing at 0.49. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 19.24, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 0.55 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 8.32, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Transaction Codes To Focus On</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001179929">Check Out The Full List Of Molina Healthcare's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Molina Healthcare Chief Legal Officer Trades $1.79M In Company Stock

A substantial insider sell was reported on July 30, by Steven J Orlando, Board Member at Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), based on the recent SEC filing.
What Happened: Orlando's recent move involves selling 1,000 shares of Molina Healthcare. This information is documented in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001179929/000117992924000127//Archives/edgar/data/1179929/000117992924000127/0001179929-24-000127-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The total value is $339,210.
The latest update on Wednesday morning shows Molina Healthcare shares down by 1.64%, trading at $344.99.
<h3>Unveiling the Story Behind Molina Healthcare</h3>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Molina Healthcare: Delving into Financials</h3>
Revenue Growth: Molina Healthcare displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 18.65%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 12.29%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Molina Healthcare's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 5.18.
</li>
</ul>
Debt Management: Molina Healthcare's debt-to-equity ratio stands notably higher than the industry average, reaching 0.49. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 19.24 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 0.55 is lower than the industry average, implying a discounted valuation for Molina Healthcare's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 8.32 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001179929">Check Out The Full List Of Molina Healthcare's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Unloading: Steven J Orlando Sells $339K Worth Of Molina Healthcare Shares

Does August's Rollercoaster Change Anything For Stocks?

An announcement from Molina Healthcare (MOH) is now available. Molina Healthcare, Inc. has made a strategic move to secure the leadership of Joseph...

Molina Healthcare Incentivizes CEO for Long-Term Leadership

Molina CEO Zubretsky to stay on through end of 2027

Molina CEO Zubretsky to stay on through the end of 2027

In a report released yesterday, Steve Baxter from Wells Fargo maintained a Hold rating on Molina Healthcare (MOH – Research Report), with a price t...

Wells Fargo Sticks to Their Hold Rating for Molina Healthcare (MOH)

Centene stock drops 8% amid lowered Medicaid forecast

Fidelity Growth Strategies Fund Q2 2024 Review

FOMC Preview: How Might Markets React After The Widely Expected Rate Cut

IHF: Healthcare Dashboard For September

TCW Relative Value Mid Cap Fund Q2 2024 Commentary

ACGL

ACGLN

ACGLO

ACHC

AKAM

ALGN

ALKS

ALLY

APOS

COLL

COST

CPAY

CVNA

DXCM

EXEL

FBCG

FBCV

FBND

FBTC

FCLD

FCOM

FCOR

FCPI

FDHY

FDIG

FDIS

FDLO

FDMO

FDRR

FDVV

FENY

FETH

FHLC

FIDI

FIDU

FLEX

FMAG

FMAT

FMET

FNCL

FQAL

FREL

FSMD

FSTA

FTEC

FUTY

FVAL

GEHC

HBAN

HBANL

HBANM

HBANP

HRMY

IDXX

INVA

MSCI

ONEQ

PLTR

PODD

RIVN

SBUX

SPOT

STLA

TSLA

VEEV

Press Releases

Molina Healthcare Wins Michigan Medicaid Contract

Molina Healthcare Reports First Quarter 2024 Financial Results

Molina Healthcare of Wisconsin Receives Notice of Intent to Award New Region 5 Contract

Molina Healthcare Announces Second Quarter 2024 Earnings Release and Conference Call Dates

Molina Healthcare Awarded New Florida Medicaid Contract

Molina Healthcare to Acquire ConnectiCare

Molina Healthcare Reports Second Quarter 2024 Financial Results

Molina Healthcare Signs CEO Joe Zubretsky to New Employment Agreement

Molina Healthcare Senior Executive Vice President and CFO Mark Keim to Expand Role to Include Leadership of the Medicaid Health Plans and Marketplace Business

Molina Healthcare Announces Third Quarter 2024 Earnings Release and Conference Call Dates and Investor Day Meeting

Comments

Molina Healthcare

Actualités

Dernières nouvelles pour Molina Healthcare (NYSE:MOH) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL